Endo shutters a pain program following trial failure

There will be no third act for Endo's pain drug partnership with Grunenthal. Endo had originally signed on to the pact in early 2009, gaining U.S. marketing rights to axomadol. But earlier this summer investigators reported the disappointing news that the drug had failed a mid-stage study, and this morning the biotech company said it will shutter the program and dump the collaboration. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.